- cafead Apr 04, 2019 at 11:22: PM
via Anyone looking to see why investment bankers love big time M&A so much should check out Bristol-Myers Squibb’s new SEC filing Thursday evening.
In the leadup to its megamerger with Celgene, the pharma giant has been peppered by a slate of lawsuits from unhappy investors. And to settle one that threatened to possibly delay their deal— now facing a crucial shareholder vote next week that Bristol-Myers is widely expected to win — the Bristol-Myers team agreed to spell out the $187 million-plus in fees they’re paying to Morgan Stanley, which offered their opinion on the fairness of the buyout pact.
article source
In the leadup to its megamerger with Celgene, the pharma giant has been peppered by a slate of lawsuits from unhappy investors. And to settle one that threatened to possibly delay their deal— now facing a crucial shareholder vote next week that Bristol-Myers is widely expected to win — the Bristol-Myers team agreed to spell out the $187 million-plus in fees they’re paying to Morgan Stanley, which offered their opinion on the fairness of the buyout pact.
article source